KYSA-8
Asset
Autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy depleting B cells.
- Stage
- Phase 2
- Modality
- Cell therapy
- Target
- CD19
- 2
- Indications
- 0
- Trials
- 1
- Developer
Indications
2Stiff person syndrome
Phase 2, globenewswire.com, 7 Oct 2026
Progressive multiple sclerosis
Human trials, globenewswire.com, 7 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Evidence for its targets1
- Competitors4
Every asset’s record: target, stage, trials and the evidence behind it.